Innate Pharma : IPH4102 va bien entrer en phase 2 au S1 2019
>Des résultats de phase 1 qui “poussent†à la phase 2 - Innate Pharma a publié, avant hier soir au congrès ASH, de nouvelles données de sa phase 1 avec IPH4102 pour les patients atteints d’un syndrome de Sézary (SS) – un type rare de lymphome T cutané (LTC - environ 6000 patients par année aux USA et en Europe). Ce cancer se caractérise par une infiltration de LT malins dans la peau et un taux de survie à 5 ans d’environ 10%, il est généralement diagnostiqué vers l’âg...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.